RP1L1

RP1L1 makes a retina-specific protein that belongs to the doublecortin family, meaning it contains regions that attach to microtubules, the tiny internal scaffolding that helps cells hold their shape. The protein works alongside a closely related protein called RP1 inside rod photoreceptors, the cells that handle dim-light and peripheral vision. Together these two proteins help build and maintain the photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) outer segment. Because the protein is found only in the retina, the effects of RP1L1 changes are expected to be limited to the eye. You may see this gene written under older or alternative names, such as OCMD or RP88.

The most frequently reported effect is occult macular dystrophy, sometimes called Miyake disease, in which people notice a gradual decline in central vision even though the back of the eye looks essentially normal. Because the fundus appears normal, the diagnosis often relies on specialized testing such as a focal or multifocal electroretinogram (definition: A test (often abbreviated ERG) that measures the retina's electrical response to light, used to check how well photoreceptors are working.), which measures the electrical response of the small central area of the retina. In one multicenter cohort, central vision declined slowly; on average, by roughly half a line on the eye chart per year. Because the cone cells responsible for color are affected, participants described in studies may also have reduced color discrimination. The range of possible presentations is broader than occult macular dystrophy alone. These have included retinitis pigmentosa, atypical macular dystrophy, and a vitelliform (yolk-like) maculopathy. Age of onset, severity, and how quickly vision changes have varied considerably from person to person.

Autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) occult macular dystrophy is the most commonly reported form of RP1L1-associated disease, meaning a single altered copy of the gene can be enough to cause it. One specific change, c.133C>T (also written p.Arg45Trp or R45W), is the most frequently identified variant across different populations. In studies to date, the R45W change has been associated with earlier onset and more severe vision loss than some other RP1L1 variants. Less commonly, RP1L1 disease can follow a recessive pattern, where two altered copies are involved, and these cases have included retinitis pigmentosa.

The underlying biological process that drives RP1L1-associated occult macular dystrophy is still not fully understood. Not everyone who carries an RP1L1 variant develops symptoms; studies have found unaffected relatives carrying the same change, pointing to incomplete penetrance, meaning a variant does not always lead to disease. This makes interpreting a single RP1L1 result difficult, because the gene is also naturally variable in length among healthy people. In rare reports, a combination of changes in RP1L1 and a second gene was proposed to contribute to a syndromic retinal condition, but such digenic (two-gene) explanations remain uncommon and not firmly established. Whether the vitelliform (yolk-like) presentation is a separate pathway or part of the same spectrum is still being clarified, with at least one pediatric case showing a fluctuating course over several years.

As of this review, no treatment targeting RP1L1 has been approved, and the available studies describe no gene-specific therapy currently in use. Research is active but at an early, laboratory stage. Scientists have created a zebrafish model and patient-derived stem cell lines to study how RP1L1 changes damage photoreceptors. One recent study sequenced dozens of families and reported that the R45W change disrupts where the protein sits inside the cell and affects cell survival, offering possible leads for future therapy. These are mechanisms being explored in cells and animals, not treatments available to patients.

• How RP1L1 variants may cause occult macular dystrophy

  Human genetic study combined with laboratory cell experiments.

  What was found:

  The R45W variant was the most common finding and was linked to earlier onset and more severe disease; in laboratory cells it disrupted where the RP1L1 and RP1 proteins were located and reduced cell viability.

  Why it matters:

  It strengthens the case that RP1L1 variants cause the disease and points to possible biological targets for future research.

  Limitation: The mechanistic findings come from cells, not people, and the underlying disease process is still described as not fully understood.

• A zebrafish model of RP1L1 photoreceptor disease

  Preclinical animal (zebrafish) study.

  What was found:

  The fish developed progressive photoreceptor dysfunction, disorganized photoreceptors, thinner retinas, and deposits resembling features of age-related macular degeneration.

  Why it matters:

  It provides an animal model to study disease mechanisms and test future approaches.

  Limitation: Findings in fish do not directly translate to human treatment and are not a therapy.

• The range of RP1L1-associated retinal disease

  Observational multicenter cohort study in people.

  What was found:

  Most had autosomal dominant occult macular dystrophy, but some had retinitis pigmentosa or atypical forms, and central vision declined slowly over follow-up.

  Why it matters:

  It shows that a single gene can produce several different retinal conditions, which matters for interpreting a genetic result.

  Limitation: The number of patients was small and follow-up was limited, so progression estimates are approximate.

• Varied presentations in Chinese patients, including a vitelliform case

  Small observational case series in people.

  What was found:

  Most carried the R45W variant with central vision loss, while other variants produced milder disease, and one unusual case showed a vitelliform (yolk-like) pattern.

  Why it matters:

  It illustrates how different RP1L1 variants can lead to different severities and appearances.

  Limitation: Very few patients were studied, limiting broad conclusions.

• RP1L1 variants across a spectrum including retinitis pigmentosa

  Human genetic association study.

  What was found:

  A homozygous (two-copy) RP1L1 change was found in a family with retinitis pigmentosa, while occult macular dystrophy cases carried heterozygous variants, and several unaffected relatives carried the same variants.

  Why it matters:

  It highlights both the diverse disease associations and the incomplete penetrance that complicate interpretation.

  Limitation: The finding of carriers without symptoms means a variant alone does not confirm disease.

Inheritance for RP1L1 can be dominant or, less often, recessive, so the implications for relatives depend on the specific variant and pattern identified. Families should be aware that a carried variant does not always cause symptoms. Therefore, an unaffected relative may be a carrier but not present symptons. Onset can occur in childhood. Therefore, if a young family member experiences unexplained central vision changes, it may be beneficiail to seek an evaluation even when the eye looks normal.

• Which RP1L1 variant was identified in my case, and is it thought to act in a dominant or recessive way?
• Does my clinical picture fit occult macular dystrophy, retinitis pigmentosa, or another presentation linked to this gene?
• What tests, such as multifocal electroretinography or OCT imaging, would best track my central vision over time?
• Given reports that some relatives carry the same variant without symptoms, what would testing mean for my family members?
• How often should my vision be monitored based on my specific variant?
• Are there any registries or research studies focused on RP1L1 that might be appropriate for me to learn about?

Because occult macular dystrophy can be missed on a routine exam, specialized electrophysiology and imaging are often needed, and these are worth discussing with a retinal specialist. Confirming the specific RP1L1 variant and its inheritance pattern through genetic counseling can help clarify what the result means for you and your relatives. If you are interested in research opportunities, RP Hope's Clinical Trials Finder can help you screen studies with RP1L1 in mind.